Dr. Bunn on Initial Results of the MYSTIC Trial in Stage IV Lung Cancer

Paul A. Bunn, MD
Published: Thursday, Jul 27, 2017


Paul A. Bunn, MD, distinguished professor, Division of Medical Oncology, and James Dudley Chair in Lung Cancer Research, University of Colorado, discusses the initial results of the ongoing MYSTIC trial, which is exploring the combination of durvalumab (Imfinzi) and tremelimumab versus chemotherapy in stage IV lung cancer.

Though the full results are not available yet, Bunn says we do know the study did not meet its primary endpoint of progression-free survival (PFS). Bunn was hopeful that the combination of 2 immunotherapy agents would be better than 1 immunotherapy agent, so he is disappointed in the results. However, before making any major conclusions, Bunn says he wants to see the subset analyses. In addition, he notes that sometimes overall survival can be positive, even when PFS is not.

Paul A. Bunn, MD, distinguished professor, Division of Medical Oncology, and James Dudley Chair in Lung Cancer Research, University of Colorado, discusses the initial results of the ongoing MYSTIC trial, which is exploring the combination of durvalumab (Imfinzi) and tremelimumab versus chemotherapy in stage IV lung cancer.

Though the full results are not available yet, Bunn says we do know the study did not meet its primary endpoint of progression-free survival (PFS). Bunn was hopeful that the combination of 2 immunotherapy agents would be better than 1 immunotherapy agent, so he is disappointed in the results. However, before making any major conclusions, Bunn says he wants to see the subset analyses. In addition, he notes that sometimes overall survival can be positive, even when PFS is not.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x